Agios Pharmaceuticals, Inc. (AGIO) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to AGO's first quarter 2025 conference call. At this time, all participants are on a listen-only mode. There will be a question-answer session at the end. Please be advised that this call is being recorded at AGO's request. I would like to turn the call over to Chris Taylor, Vice President of Investor Relations and Corporate Communications for AGOs. Thank you, Operator. Good morning, everyone, and welcome to AGIOS conference call and webcast to discuss our first quarter 2025 financial results and recent business highlights. You can access the slides for today's call by going to the investors section of our website, agios.com. On today's call, we'll hear from our Chief Executive Officer, Brian Goff, Dr. Sarah Hewins, Chief Medical Officer and Head of Research and Development, Sveta Milanova, Chief Commercial Officer, and Cecilia Jones, Chief Financial Officer. Before we get started, I would like to remind everyone that some of the statements we make on this call will include forward-looking statements. Actual events and results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties, and other factors, including those set forth in our most recent filings with the SEC. and any other future filings that we may make with the SEC. And with that, I'm pleased to turn the call over to Brian. Thanks, Chris. Good morning, everyone, and thank you for joining us. Our mission at Agios is to develop and deliver transformative medicines that elevate and extend the lives of patients living with rare diseases. Today, we are fortunate to have multiple late-stage programs nearing critical readouts or potential commercialization. and have a very strong balance sheet. We are maintaining...